{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T16:30:34Z","timestamp":1793896234127,"version":"4.8.0"},"reference-count":35,"publisher":"Wiley","issue":"14","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2023,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Continuous ibrutinib administration is needed to maintain efficacy in patients with chronic lymphocytic leukemia (CLL) and, as such, long\u2010term toxicity is a concern. The authors report the 5\u2010year follow\u2010up of patients with CLL who received treatment with ibrutinib with a focus on hypertension and cardiovascular toxicities.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient characteristics were assessed, including blood pressure, cardiovascular disease, disease progression, and death. Univariate logistic regression analysis assessed the relation of patient characteristics and the development of new or worsened hypertension. The incidence of hypertensive outcomes was evaluated using competing risk. Survival was estimated using the Kaplan\u2013Meier method.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred patients with CLL who were treated with ibrutinib on clinical trials were included. The median patient age at study enrollment was 65\u00a0years (range, 29\u201383\u00a0years). Seventy percent of patients were men, and 88% were Caucasian. Sixty\u2010nine percent of patients had hypertension at baseline, and 47% were on antihypertensive medication. Eighty\u2010eight percent had relapsed or refractory CLL. New\u2010onset and worsening hypertension were common, occurring in 68.5% and 38% of patients, respectively. Systolic blood pressure \u2265160 mm Hg or diastolic blood pressure \u2265100 mm Hg was observed in 16.9% of patients. Hypertension was reversible after ibrutinib discontinuation. Older age, male sex, tobacco use, and chronic kidney disease were associated with ibrutinib\u2010related hypertension. Baseline hypertension was not associated with major adverse cardiovascular events in ibrutinib\u2010treated patients nor with event\u2010free or overall survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Hypertension is a common toxicity in patients with CLL who receive ibrutinib but is manageable in most patients. Other than chronic kidney disease, baseline cardiovascular disease did not affect ibrutinib\u2010related hypertension nor was hypertension associated with major adverse cardiovascular events or survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Plain Language Summary<\/jats:title><jats:p>\n<jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Ibrutinib is an effective treatment for patients with chronic lymphocytic leukemia.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Ibrutinib is a well tolerated therapy, however hypertension can develop or worsen in patients receiving ibrutinib and other cardiovascular events are significant challenges to the use of this drug.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>This may be particularly true in patients with heart disease.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Short\u2010term side effects may worsen heart disease, but the long\u2010term impact is unknown.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>The long\u2010term results of ibrutinib on heart disease and hypertension are described.<\/jats:p><\/jats:list-item>\n<\/jats:list>\n<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.34787","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T03:38:33Z","timestamp":1680665913000},"page":"2192-2200","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Long\u2010term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity"],"prefix":"10.1002","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3940-4451","authenticated-orcid":false,"given":"Max J.","family":"Gordon","sequence":"first","affiliation":[{"name":"Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade E.","family":"Jones","sequence":"additional","affiliation":[{"name":"Division of Cancer Medicine The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binsah","family":"George","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Division of Cancer Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Biostatistics The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan A.","family":"Burger","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Division of Cancer Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Division of Cancer Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Keating","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Division of Cancer Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Wierda","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Division of Cancer Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Bernard","family":"Durand","sequence":"additional","affiliation":[{"name":"Department of Cardiology The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas MD Anderson Cancer Center Division of Cancer Medicine  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201009\u2010806398"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600\u2010065x.2008.00741.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.182.1.329"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1215637"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1400376"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010019\u20100602\u2010x"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1509388"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102018\u201008\u2010870238"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1817073"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1812836"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.182907"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31554"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201012\u2010820910"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16326"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.171041"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028761"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYP.0000000000000066"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1511939"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1996.03530440037034"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1803180"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.9.1207"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.8.923"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701724785"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14785"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.33_2879"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002\u20108703(91)90861\u2010b"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01210"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2211582"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102017\u201003\u2010772285"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102022\u2010159632"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3993"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102020\u2010137024"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.34787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T15:23:40Z","timestamp":1760282620000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.34787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":35,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,15]]}},"alternative-id":["10.1002\/cncr.34787"],"URL":"https:\/\/doi.org\/10.1002\/cncr.34787","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"2023-01-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-28","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}